The Lancet Diabetes & Endocrinology
IF
19.31
Papers
1338
Papers 1325
1 page of 133 pages (1,325 results)
Newest
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Frederic Castinetti1
Estimated H-index: 1
(French Institute of Health and Medical Research),
Steven G Waguespack37
Estimated H-index: 37
(University of Texas MD Anderson Cancer Center)
+ 63 AuthorsRossella Elisei58
Estimated H-index: 58
Summary Background Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. Methods This study was a retrospective,...
Source Cite
Published on Apr 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Jules Morgan1
Estimated H-index: 1
Source Cite
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Lindsay M. Jaacks12
Estimated H-index: 12
(Harvard University),
Stefanie Vandevijvere7
Estimated H-index: 7
(University of Auckland)
+ 6 AuthorsMajid Ezzati98
Estimated H-index: 98
(Imperial College London)
Summary The global prevalence of obesity has increased substantially over the past 40 years, from less than 1% in 1975, to 6–8% in 2016, among girls and boys, and from 3% to 11% among men and from 6% to 15% among women over the same time period. Our aim was to consolidate the evidence on the epidemiology of obesity into a conceptual model of the so-called obesity transition. We used illustrative examples from the 30 most populous countries, representing 77·5% of the world's population to propose...
Source Cite
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Inge B Halberg1
Estimated H-index: 1
(Novo Nordisk),
Karsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
+ 3 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Summary Background Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. Methods This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequatel...
3 Citations Source Cite
Published on Jan 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Jeannie Tay (University of Alabama at Birmingham), Martin de Bock1
Estimated H-index: 1
(University of Otago),
Elizabeth J. Mayer-Davis65
Estimated H-index: 65
(University of North Carolina at Chapel Hill)
Source Cite
Published on Apr 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Tone Shetelig Løvvik2
Estimated H-index: 2
(Norwegian University of Science and Technology),
Sven M. Carlsen24
Estimated H-index: 24
(Norwegian University of Science and Technology)
+ 16 AuthorsAngelica Lindén Hirschberg31
Estimated H-index: 31
(Karolinska Institutet)
Summary Background Women with polycystic ovary syndrome (PCOS) have an increased risk of pregnancy complications. Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group. The aim of this third randomised trial (PregMet2) was to test the hypothesis that metformin prevents late miscarriage and preterm birth in women with PCOS. Meth...
1 Citations Source Cite
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Chantal Mathieu77
Estimated H-index: 77
Source Cite
Published on Feb 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Charumathi Sabanayagam28
Estimated H-index: 28
(National University of Singapore),
Riswana Banu + 11 AuthorsB.E. K. Klein149
Estimated H-index: 149
(University of Wisconsin-Madison)
Summary Diabetic retinopathy is a leading cause of vision impairment and blindness. We systematically reviewed studies published from Jan 1, 1980, to Jan 7, 2018, assessed the methodological quality, and described variations in incidence of diabetic retinopathy by region with a focus on population-based studies that were conducted after 2000 (n=8, including two unpublished studies). Of these eight studies, five were from Asia, and one each from the North America, Caribbean, and sub-Saharan Afric...
Source Cite
Published on Jan 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Mark A. Atkinson82
Estimated H-index: 82
(University of Florida),
Bart O. Roep58
Estimated H-index: 58
(City of Hope National Medical Center)
+ 2 AuthorsMark Peakman51
Estimated H-index: 51
(HealthPartners)
Summary With the conceptual advance about four decades ago that type 1 diabetes represents an autoimmune disease, hope arose that immune-based therapies would soon emerge to prevent and reverse the disorder. However, despite dozens of clinical trials seeking to achieve these goals, the promise remains unfulfilled, at least in a pragmatic form. With the benefit of hindsight, several important reasons are likely to account for this disappointing outcome, including failure to appreciate disease het...
1 Citations Source Cite
Published on Apr 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Onyebuchi E. Okosieme16
Estimated H-index: 16
(Cardiff University),
Peter N. Taylor12
Estimated H-index: 12
(Cardiff University)
+ 11 AuthorsAdrian E Sayers21
Estimated H-index: 21
(University of Bristol)
Summary Background Graves' disease is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncertain. We evaluated cardiovascular morbidity and mortality according to the method and effectiveness of primary therapy in Graves' disease. Methods In this retrospective cohort study, we identified patients with hyperthyroidism, diagnosed between Jan 1, 1998, and Dec 31, 2013, from a thyroid-stimulating hormone (TS...
1 Citations Source Cite
12345678910